Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

Perrigo Company plc

PRGO

FAVORABLE

June 1, 2026

Research Conclusion

At $11.22, Perrigo offers asymmetric upside as a deleveraging-execution play with a triangulated fair value of ~$16 (+43%). The setup is contingent on Project Energize delivering ~$130M net savings by FY2027, Dermacosmetics divestiture closing at >$250M, and CSCA organic decline narrowing to zero by end FY2027. With ~10% dividend yield providing a return floor, institutional buyers building positions, and reverse-DCF showing the market prices essentially zero benefit from the operational program, this is a speculative-value position appropriate for small-to-medium portfolio sizing.

Company Overview & Moat Assessment

Perrigo Company plc (NYSE: PRGO; Dublin, Ireland) is the world's largest manufacturer of over-the-counter (OTC) store-brand consumer healthcare products. The company operates two segments: Consumer Self-Care Americas (CSCA, ~60% of revenue)—the dominant US private-label OTC supplier with >50% US store-brand OTC market share—and Consumer Self-Care International (CSCI, ~40%)—a branded European OTC portfolio (Compeed, Solpadeine, Coldrex, ellaOne, Plan B) enlarged by the €1.8B 2022 HRA Pharma acquisition. FY2025 revenue was $4.25B; leverage is ~5-7x adj. EBITDA. The equity story depends on Project Energize cost restructuring, Dermacosmetics divestiture, infant formula strategic review, and Opill—the first OTC daily oral contraceptive in US history.

▲ Bull Case

  • ◆Project Energize delivers $130M+ net savings by end FY2027 + Opill ramps to $200M FY2028. Adj. EBITDA expands from ~$425M (FY2025) to $595M+ (FY2030); FCF inflects from $145M to $390M+; equity re-rates as deleveraging path becomes visible.
  • ◆Dermacosmetics closes at full €327M ask; infant formula sale brings $300M+ in proceeds; combined ~$650M debt paydown in 18 months. Net debt falls below $2.5B by end FY2027, triggering re-rating from 9.5x to 12x EV/EBITDA.
  • ◆Consumer trade-down + CSCA organic inflection. Persistent inflation drives private-label market share gains; CSCA organic growth turns positive in 2H 2026 (+1–3%). Combined with 10% dividend yield, total return potential exceeds 80% over 24 months.

▼ Bear Case

  • ◆Energize savings offset by CSCA pricing concessions; revenue declines continue. FY2027 adj. EBITDA stuck near $430M; leverage stays above 5x; FCF remains below dividend. Stock revisits 52-week low ($9.22).
  • ◆Dividend cut at 50–75% becomes inevitable by mid-2027. $145M FY2025 FCF vs. $159M dividend is mathematically unsustainable; income investors exit; near-term stock pressure to $7–9.
  • ◆Infant formula sale fails to find buyer; CSCI continues underperformance. Carrying value impairment of $300M+ tests equity buffer; remaining $4.4B goodwill/intangibles susceptible to further write-downs.
Primary Debate on Wall Street

“The consensus debate centers on timing and execution of deleveraging, not strategy itself. 5 covering analysts (2 Buy / 3 Hold / 0 Sell; average PT $16.50, +47% upside) agree PRGO is structurally undervalued vs. peers, the deleveraging path is plausible if execution holds, and Dermacosmetics is a binary catalyst. Bull camp argues leverage discount is over-priced and multiple expansion is mechanical as debt reduces, with Opill as hidden upside. Bear camp contends structural revenue decline is incompatible with cost savings and dividend is unsustainable. Hold camp prefers to wait for Q2/Q3 2026 adj. EBITDA margin inflection. The most differentiated thesis is that management should voluntarily cut the dividend by 75% to accelerate deleveraging, but consensus prices a cut as negative.”

Top Catalysts
  • ◆Q2 2026 earnings: first material Energize benefit visibility (Aug 2026)—High impact, potential first re-rating
  • ◆Dermacosmetics close confirmation + proceeds detail (H1 2026 in progress)—Material $300M+ debt paydown
  • ◆Infant formula strategic review outcome (Q2–Q3 2026)—Binary $300–450M proceeds or negative overhang
  • ◆Project Energize FY2026 full-year savings disclosure (Q4 2026/Q1 2027)—Credibility test on $140–170M target
  • ◆Opill quarterly disclosure (if/when broken out)—High signal of revenue trajectory
  • ◆FY2027 guidance issuance (Feb 2027)—First multi-year forecast incorporating Energize run-rate
  • ◆Adj. EBITDA margin inflection (YoY expansion ≥150bps)—Re-rating trigger
  • ◆Net leverage update <5x adj. EBITDA (Q3 2026 onwards)—Sentiment shift toward deleveraging credibility
Top Risks
  • ◆Interest rate / refinancing risk (~$3.6B debt)—Medium probability, High impact
  • ◆FDA Warning Letter / manufacturing recall—Low probability, Very High impact
  • ◆Retailer concentration & pricing pressure (CSCA)—Medium probability, High impact
  • ◆Project Energize savings underdelivery vs. target—Medium probability, High impact
  • ◆Infant formula sale fails to find buyer—Medium probability, Medium impact
  • ◆Dividend forced cut / signaling event—Medium probability, Medium-High impact
  • ◆Recession (CSCI more vulnerable than CSCA)—Low-Medium probability, Medium impact
  • ◆Currency drag (EUR/GBP weakness)—Medium probability, Low-Medium impact
  • ◆Goodwill impairment (remaining $4.4B base)—Medium probability, Medium impact
  • ◆Plan B / ellaOne political risk (US)—Low-Medium probability, Low-Medium impact

Full Memo Continues

5 more sections, locked

  • ●
    Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • ●
    Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • ●
    Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • ●
    Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • ●
    Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/PRGO/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.